Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Interleukin-12 may kill tumor cells by stopping blood
flow to the tumor and by stimulating a person's white blood cells to kill the tumor cells.
Combining chemotherapy with interleukin-12 may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with
interleukin-12 in treating patients who have AIDS-related Kaposi's sarcoma.